{
    "eid": "2-s2.0-85075924124",
    "title": "The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy",
    "cover-date": "2020-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Surgery",
            "@code": "2746",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "CINV prevention",
        "HEC",
        "Olanzapine",
        "Ondansetron"
    ],
    "authors": [
        "Veerisa Vimolchalao",
        "Siwat Sakdejayont",
        "Ploytuangporn Wongchanapai",
        "Shama Sukprakun",
        "Pattama Angspatt",
        "Wilai Thawinwisan",
        "Piyachut Chenaksara",
        "Virote Sriuranpong",
        "Chanida Vinayanuwatikun",
        "Napa Parinyanitikun",
        "Nattaya Poovorawan",
        "Suebpong Tanasanvimon"
    ],
    "citedby-count": 10,
    "ref-count": 25,
    "ref-list": [
        "Conditionability of cancer chemotherapy patients",
        "Gastrointestinal toxicity of chemotherapeutic agents",
        "The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy",
        "Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment",
        "In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug",
        "Olanzapine. Pharmacokinetic and pharmacodynamic profile",
        "Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer",
        "A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients",
        "A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain",
        "A phase i trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: a hoosier oncology group study",
        "Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (cinv): a systematic review and meta-analysis",
        "Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting",
        "Olanzapine for the prevention of chemotherapy-induced nausea and vomiting",
        "NCCN guidelines insights: Antiemesis, version 2.2017",
        "Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update",
        "A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition",
        "New generation antipsychotic drugs and QTc interval prolongation",
        "Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study",
        "Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial",
        "Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting",
        "Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study",
        "Capecitabine as adjuvant treatment for stage III colon cancer",
        "Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting",
        "Antiemesis",
        "Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60025527",
            "affilname": "Faculty of Medicine, Prince of Songkia University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025527",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn Medical Oncology Research Fund",
        "Chulalongkorn University supporting fund for thesis",
        "Chulalongkorn University"
    ]
}